Shots: The US FDA has accepted the sBLA for a new self-administration option for Xolair across all approved indications in the US. The company anticipates the approval of the therapy […]readmore
Tags : (omalizumab)
Shots: The sBLA submission is based on P-III POLYP 1 & 2 studies assessing Xolair (SC) vs PBO in 138 & 127 patients with CRSwNP with inadequate response to intranasal […]readmore
Shots: Celltrion plans for the onset of P-I trial for CT-P39 referencing Xolair, and further plans to enter P-III trial in H1’20 with its expected commercialization by 2020 The P-I […]readmore
Shots: The P-III POLYP 1 & POLYP 2 studies results involve assessing of Xolair (SC, q2w/q4w) vs PBO in 138 & 127 patients with CRSwNP with inadequate response to intranasal […]readmore
Shots: The approval is based on trial results assessing Xolair IV (q2w or q4w) in 1M patients with SAA and CSU for 13 years The study demonstrated in reduction of severe exacerbations, corticosteroid […]readmore